伦敦癌症研究所(ICR):palbociclib有望治疗三阴性乳腺癌

2021-01-28 Allan MedSci原创

伦敦癌症研究所(ICR)的研究人员指出,palbociclib有望在三阴性乳腺癌(TNBC)中发挥作用。

伦敦癌症研究所(ICR)的研究人员指出,palbociclib有望在三阴性乳腺癌(TNBC)中发挥作用。

这项由慈善机构(Beast Cancer Now)资助的研究表明,palbociclib可用于治疗大约五分之一的TNBC患者。该研究发现了一种识别TNBC肿瘤的方法,该肿瘤更可能对CDK4 / 6抑制剂(例如palbociclib)产生反应。

ICR研究人员发现,CREBBP蛋白水平降低的TNBC细胞可以更快速地生长。研究小组使用两个大型患者数据库进一步研究了低CREBBP水平的作用,发现低CREBBP水平与TNBC患者的生存期较差有关。此外,低水平的CREBBP还发生在许多其他癌症中,包括子宫癌、卵巢癌以及一些肺癌和膀胱癌,这表明它在肿瘤的发生或发展中起着至关重要的作用。至关重要的是,研究人员发现,当这种蛋白质处于低水平时,它们依赖CDK4和CDK6蛋白来促进细胞增殖。

 

原始出处:

http://www.pharmatimes.com/news/researchers_identify_existing_drugs_promise_for_triple_negative_breast_cancer_1362155

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2048080, encodeId=f823204808044, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Fri Feb 05 21:46:51 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801077, encodeId=ad4f18010e7e0, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Fri May 14 05:46:51 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372325, encodeId=a93f13e23259f, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458800, encodeId=b2ab1458800fb, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514200, encodeId=b8351514200aa, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921034, encodeId=142392103495, content=期待乳腺癌治疗突破 , beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/11/07/32f6eeca95f16df602e2fe81e7416090.jpg, createdBy=ddb32421444, createdName=精气神, createdTime=Fri Jan 29 13:50:45 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920955, encodeId=674c92095543, content=123, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210129/1f7bcc47e19e459f84f162cbdd4e7e4c/f96be1903e2644a39fb32c7d667dbc9c.jpg, createdBy=312c5456893, createdName=ms温馨, createdTime=Fri Jan 29 10:38:48 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920852, encodeId=23e492085251, content=好好学习也, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Thu Jan 28 21:56:11 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920850, encodeId=e84892085085, content=这个很好,需要好好学习了<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Thu Jan 28 21:55:13 CST 2021, time=2021-01-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2048080, encodeId=f823204808044, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Fri Feb 05 21:46:51 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801077, encodeId=ad4f18010e7e0, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Fri May 14 05:46:51 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372325, encodeId=a93f13e23259f, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458800, encodeId=b2ab1458800fb, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514200, encodeId=b8351514200aa, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921034, encodeId=142392103495, content=期待乳腺癌治疗突破 , beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/11/07/32f6eeca95f16df602e2fe81e7416090.jpg, createdBy=ddb32421444, createdName=精气神, createdTime=Fri Jan 29 13:50:45 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920955, encodeId=674c92095543, content=123, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210129/1f7bcc47e19e459f84f162cbdd4e7e4c/f96be1903e2644a39fb32c7d667dbc9c.jpg, createdBy=312c5456893, createdName=ms温馨, createdTime=Fri Jan 29 10:38:48 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920852, encodeId=23e492085251, content=好好学习也, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Thu Jan 28 21:56:11 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920850, encodeId=e84892085085, content=这个很好,需要好好学习了<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Thu Jan 28 21:55:13 CST 2021, time=2021-01-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2048080, encodeId=f823204808044, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Fri Feb 05 21:46:51 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801077, encodeId=ad4f18010e7e0, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Fri May 14 05:46:51 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372325, encodeId=a93f13e23259f, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458800, encodeId=b2ab1458800fb, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514200, encodeId=b8351514200aa, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921034, encodeId=142392103495, content=期待乳腺癌治疗突破 , beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/11/07/32f6eeca95f16df602e2fe81e7416090.jpg, createdBy=ddb32421444, createdName=精气神, createdTime=Fri Jan 29 13:50:45 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920955, encodeId=674c92095543, content=123, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210129/1f7bcc47e19e459f84f162cbdd4e7e4c/f96be1903e2644a39fb32c7d667dbc9c.jpg, createdBy=312c5456893, createdName=ms温馨, createdTime=Fri Jan 29 10:38:48 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920852, encodeId=23e492085251, content=好好学习也, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Thu Jan 28 21:56:11 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920850, encodeId=e84892085085, content=这个很好,需要好好学习了<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Thu Jan 28 21:55:13 CST 2021, time=2021-01-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2048080, encodeId=f823204808044, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Fri Feb 05 21:46:51 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801077, encodeId=ad4f18010e7e0, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Fri May 14 05:46:51 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372325, encodeId=a93f13e23259f, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458800, encodeId=b2ab1458800fb, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514200, encodeId=b8351514200aa, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921034, encodeId=142392103495, content=期待乳腺癌治疗突破 , beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/11/07/32f6eeca95f16df602e2fe81e7416090.jpg, createdBy=ddb32421444, createdName=精气神, createdTime=Fri Jan 29 13:50:45 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920955, encodeId=674c92095543, content=123, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210129/1f7bcc47e19e459f84f162cbdd4e7e4c/f96be1903e2644a39fb32c7d667dbc9c.jpg, createdBy=312c5456893, createdName=ms温馨, createdTime=Fri Jan 29 10:38:48 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920852, encodeId=23e492085251, content=好好学习也, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Thu Jan 28 21:56:11 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920850, encodeId=e84892085085, content=这个很好,需要好好学习了<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Thu Jan 28 21:55:13 CST 2021, time=2021-01-28, status=1, ipAttribution=)]
    2021-01-30 xlysu
  5. [GetPortalCommentsPageByObjectIdResponse(id=2048080, encodeId=f823204808044, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Fri Feb 05 21:46:51 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801077, encodeId=ad4f18010e7e0, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Fri May 14 05:46:51 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372325, encodeId=a93f13e23259f, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458800, encodeId=b2ab1458800fb, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514200, encodeId=b8351514200aa, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921034, encodeId=142392103495, content=期待乳腺癌治疗突破 , beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/11/07/32f6eeca95f16df602e2fe81e7416090.jpg, createdBy=ddb32421444, createdName=精气神, createdTime=Fri Jan 29 13:50:45 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920955, encodeId=674c92095543, content=123, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210129/1f7bcc47e19e459f84f162cbdd4e7e4c/f96be1903e2644a39fb32c7d667dbc9c.jpg, createdBy=312c5456893, createdName=ms温馨, createdTime=Fri Jan 29 10:38:48 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920852, encodeId=23e492085251, content=好好学习也, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Thu Jan 28 21:56:11 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920850, encodeId=e84892085085, content=这个很好,需要好好学习了<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Thu Jan 28 21:55:13 CST 2021, time=2021-01-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2048080, encodeId=f823204808044, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Fri Feb 05 21:46:51 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801077, encodeId=ad4f18010e7e0, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Fri May 14 05:46:51 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372325, encodeId=a93f13e23259f, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458800, encodeId=b2ab1458800fb, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514200, encodeId=b8351514200aa, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921034, encodeId=142392103495, content=期待乳腺癌治疗突破 , beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/11/07/32f6eeca95f16df602e2fe81e7416090.jpg, createdBy=ddb32421444, createdName=精气神, createdTime=Fri Jan 29 13:50:45 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920955, encodeId=674c92095543, content=123, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210129/1f7bcc47e19e459f84f162cbdd4e7e4c/f96be1903e2644a39fb32c7d667dbc9c.jpg, createdBy=312c5456893, createdName=ms温馨, createdTime=Fri Jan 29 10:38:48 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920852, encodeId=23e492085251, content=好好学习也, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Thu Jan 28 21:56:11 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920850, encodeId=e84892085085, content=这个很好,需要好好学习了<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Thu Jan 28 21:55:13 CST 2021, time=2021-01-28, status=1, ipAttribution=)]
    2021-01-29 精气神

    期待乳腺癌治疗突破

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2048080, encodeId=f823204808044, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Fri Feb 05 21:46:51 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801077, encodeId=ad4f18010e7e0, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Fri May 14 05:46:51 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372325, encodeId=a93f13e23259f, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458800, encodeId=b2ab1458800fb, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514200, encodeId=b8351514200aa, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921034, encodeId=142392103495, content=期待乳腺癌治疗突破 , beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/11/07/32f6eeca95f16df602e2fe81e7416090.jpg, createdBy=ddb32421444, createdName=精气神, createdTime=Fri Jan 29 13:50:45 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920955, encodeId=674c92095543, content=123, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210129/1f7bcc47e19e459f84f162cbdd4e7e4c/f96be1903e2644a39fb32c7d667dbc9c.jpg, createdBy=312c5456893, createdName=ms温馨, createdTime=Fri Jan 29 10:38:48 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920852, encodeId=23e492085251, content=好好学习也, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Thu Jan 28 21:56:11 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920850, encodeId=e84892085085, content=这个很好,需要好好学习了<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Thu Jan 28 21:55:13 CST 2021, time=2021-01-28, status=1, ipAttribution=)]
    2021-01-29 ms温馨

    123

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2048080, encodeId=f823204808044, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Fri Feb 05 21:46:51 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801077, encodeId=ad4f18010e7e0, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Fri May 14 05:46:51 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372325, encodeId=a93f13e23259f, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458800, encodeId=b2ab1458800fb, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514200, encodeId=b8351514200aa, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921034, encodeId=142392103495, content=期待乳腺癌治疗突破 , beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/11/07/32f6eeca95f16df602e2fe81e7416090.jpg, createdBy=ddb32421444, createdName=精气神, createdTime=Fri Jan 29 13:50:45 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920955, encodeId=674c92095543, content=123, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210129/1f7bcc47e19e459f84f162cbdd4e7e4c/f96be1903e2644a39fb32c7d667dbc9c.jpg, createdBy=312c5456893, createdName=ms温馨, createdTime=Fri Jan 29 10:38:48 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920852, encodeId=23e492085251, content=好好学习也, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Thu Jan 28 21:56:11 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920850, encodeId=e84892085085, content=这个很好,需要好好学习了<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Thu Jan 28 21:55:13 CST 2021, time=2021-01-28, status=1, ipAttribution=)]
    2021-01-28 水-晶

    好好学习也

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2048080, encodeId=f823204808044, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Fri Feb 05 21:46:51 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801077, encodeId=ad4f18010e7e0, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Fri May 14 05:46:51 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372325, encodeId=a93f13e23259f, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458800, encodeId=b2ab1458800fb, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514200, encodeId=b8351514200aa, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Sat Jan 30 12:46:51 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921034, encodeId=142392103495, content=期待乳腺癌治疗突破 , beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/11/07/32f6eeca95f16df602e2fe81e7416090.jpg, createdBy=ddb32421444, createdName=精气神, createdTime=Fri Jan 29 13:50:45 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920955, encodeId=674c92095543, content=123, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210129/1f7bcc47e19e459f84f162cbdd4e7e4c/f96be1903e2644a39fb32c7d667dbc9c.jpg, createdBy=312c5456893, createdName=ms温馨, createdTime=Fri Jan 29 10:38:48 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920852, encodeId=23e492085251, content=好好学习也, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Thu Jan 28 21:56:11 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920850, encodeId=e84892085085, content=这个很好,需要好好学习了<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Thu Jan 28 21:55:13 CST 2021, time=2021-01-28, status=1, ipAttribution=)]
    2021-01-28 水-晶

    这个很好,需要好好学习了#乳腺癌#

    0

相关资讯

JAMA:卡培他滨维持治疗对早期三阴性乳腺癌疗效观察的影响

标准辅助化疗后低剂量卡培他滨维持治疗是否降低早期三阴性乳腺癌复发和死亡的风险?

Cell Metab :邵志敏团队为三阴性乳腺癌“复旦分型”精准治疗策略再添新翼

三阴性乳腺癌作为乳腺癌的其中一种亚型,约占总体乳腺癌人群的10-20%,其雌激素受体、孕激素受体以及人表皮生长因子受体2表达均为阴性。这类乳腺癌恶性程度高,容易出现内脏转移,复发风险大,预后较差。

Lancet:派姆单抗联合化疗一线治疗PD-L1阳性转移性三阴性乳腺癌

对于转移性三阴性乳腺癌并伴有CPS得分10以上的患者,派姆单抗联合化疗可显著提高无进展生存期,派姆单抗可作为PD-L1高表达的转移性三阴性乳腺癌患者一线治疗手段

Eur J Cancer:BRCA1/2突变对三阴性乳腺癌新辅助化疗时发生严重血液毒性风险的影响

BRCA1和BRCA2在DNA修复中起核心作用。因此,携带胚系(g)BRCA1/2突变(m)的患者接受化疗治疗后,发生血液性毒性的风险可能更高。

Ann Oncol:奥拉帕利单一疗法在初治的三阴性乳腺癌患者中的疗效

PARP抑制剂(PARPi)对携带胚系BRCA1/2(gBRCA1/2)突变的乳腺癌患者的抗肿瘤效果是确定的。虽然PARPi单一疗法对BRCA1/2野生型转移性三阴性乳腺癌(TNBC)患者无效,但研究

Cell Death Differ:DYRK2激活HSF1增强对蛋白毒性应激反应的抵抗力并促进三阴性乳腺癌的发生发展

大约90%的实体瘤和75%的造血癌表现出一定程度的非整倍性。既往研究显示,在酵母和哺乳动物系统中,非整倍体细胞相比于整倍体细胞适应性更差。细胞会通过蛋白质降解和折叠途径调节失衡的非整倍体,而这些途径的

拓展阅读

Nature子刊:三阴性乳腺癌的罕见亚型有哪些分子特征?

本文回顾了化生性、三阴性小叶、乳腺大汗腺分化癌、腺样囊性、分泌性和高级别神经内分泌TNBC的流行病学、组织学以及临床和分子特征。

Nat. Commun | 单臂II期临床试验:卡瑞利珠单抗联合白蛋白紫杉醇和表柔比星新辅助治疗早期三阴性乳腺癌

该研究旨在评估新辅助卡瑞利珠单抗联合化疗在早期TNBC患者中的疗效和安全性,新辅助卡瑞利珠单抗联合化疗在早期TNBC患者中显示出良好的抗肿瘤活性和可控的安全性。

成中医李小芳/罗开沛《Small》:双靶向脂质体增强三阴性乳腺癌化学免疫治疗

诱导ICD并抑制STAT3,有望增强免疫原性,逆转免疫抑制。

Nat. Commun | 紫杉醇加卡铂和度伐利尤单抗联合或不联合oleclumab用于治疗既往未经治疗的局部晚期或转移性三阴性乳腺癌女性:随机SYNERGY I/II 试验

该研究旨在探索抗CD73单抗oleclumab联合化疗和抗PD-L1单抗度伐利尤单抗在未经治疗的三阴性乳腺癌患者中的安全性和疗效,该研究未达到主要终点。

JAMA Oncol | 新辅助帕博利珠单抗加卡铂和多西他赛治疗三阴性乳腺癌的临床和生物标志物结果:NeoPACT 2期临床试验

该研究旨在评估卡铂、多西他赛和帕博利珠单抗联合应用在早期三阴性乳腺癌患者新辅助治疗中的疗效,研究结果支持将非蒽环类新辅助化疗联合帕博利珠单抗方案作为化疗降级策略进行进一步随机对照研究。

Nat. Commun:抗PD-L1/CTLA-4双特异性抗体KN046联合白蛋白结合型紫杉醇一线治疗转移性三阴性乳腺癌:多中心II期试验

该研究旨在评估KN046联合白蛋白结合型紫杉醇在初治晚期TNBC中的疗效和安全性,联合方案在一线治疗晚期三阴性乳腺癌中展现出良好的疗效和安全性,尤其对PD-L1阳性患者更为显著。